284 related articles for article (PubMed ID: 22554716)
21. The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study.
Bjerre A; Aase SA; Radtke M; Siva C; Gudmundsdottir H; Forsberg B; Woldseth B; Brackman D
Pediatr Nephrol; 2023 Nov; 38(11):3671-3679. PubMed ID: 37219641
[TBL] [Abstract][Full Text] [Related]
22. Cystinosis: a new perspective.
Veys KR; Besouw MT; Pinxten AM; Dyck MV; Casteels I; Levtchenko EN
Acta Clin Belg; 2016 Jun; 71(3):131-7. PubMed ID: 25560059
[TBL] [Abstract][Full Text] [Related]
23. Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis.
Levtchenko EN; van Dael CM; de Graaf-Hess AC; Wilmer MJ; van den Heuvel LP; Monnens LA; Blom HJ
Pediatr Nephrol; 2006 Jan; 21(1):110-3. PubMed ID: 16252107
[TBL] [Abstract][Full Text] [Related]
24. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
Nesterova G; Williams C; Bernardini I; Gahl WA
Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
[TBL] [Abstract][Full Text] [Related]
25. Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom.
Lashilola S; Xu W; Azimpour K; McCarthy M; Carlot S; Game D; van der Voort J
BMC Nephrol; 2023 Nov; 24(1):351. PubMed ID: 38031005
[TBL] [Abstract][Full Text] [Related]
26. Chitotriosidase plasma activity in nephropathic cystinosis.
Xaidara A; Karavitakis EM; Kosma K; Emma F; Dimitriou E; Michelakakis H
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S157-9. PubMed ID: 19455402
[TBL] [Abstract][Full Text] [Related]
27. Parenchymal organ cystine depletion with long-term cysteamine therapy.
Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
[TBL] [Abstract][Full Text] [Related]
28. Effects of oral phosphocysteamine and rectal cysteamine in cystinosis.
van't Hoff WG; Baker T; Dalton RN; Duke LC; Smith SP; Chantler C; Haycock GB
Arch Dis Child; 1991 Dec; 66(12):1434-7. PubMed ID: 1776892
[TBL] [Abstract][Full Text] [Related]
29. Cysteamine bitartrate delayed-release capsules control leukocyte cystine levels and promote statural growth and kidney health in an open-label study of treatment-naïve patients <6 years of age with nephropathic cystinosis.
Vaisbich MH; Caires Ferreira J; Price H; Young KD; Sile S; Checani G; Langman CB
JIMD Rep; 2022 Jan; 63(1):66-79. PubMed ID: 35028272
[TBL] [Abstract][Full Text] [Related]
30. NIH conference. Cystinosis: progress in a prototypic disease.
Gahl WA; Thoene JG; Schneider JA; O'Regan S; Kaiser-Kupfer MI; Kuwabara T
Ann Intern Med; 1988 Oct; 109(7):557-69. PubMed ID: 3048161
[TBL] [Abstract][Full Text] [Related]
31. Intravenous cysteamine therapy for nephropathic cystinosis.
Gahl WA; Ingelfinger J; Mohan P; Bernardini I; Hyman PE; Tangerman A
Pediatr Res; 1995 Oct; 38(4):579-84. PubMed ID: 8559613
[TBL] [Abstract][Full Text] [Related]
32. Chitotriosidase as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis.
Veys KRP; Elmonem MA; Van Dyck M; Janssen MC; Cornelissen EAM; Hohenfellner K; Prencipe G; van den Heuvel LP; Levtchenko E
J Am Soc Nephrol; 2020 May; 31(5):1092-1106. PubMed ID: 32273301
[TBL] [Abstract][Full Text] [Related]
33. Plasma chitotriosidase enzyme activity as a novel therapeutic monitor for cysteamine treatment in nephropathic cystinosis: A retrospective validation study.
Veys K; Elmonem MA; van den Heuvel L; Gahl WA; Levtchenko E
Mol Genet Metab; 2024 May; 142(1):108454. PubMed ID: 38603816
[TBL] [Abstract][Full Text] [Related]
34. A potential new method to estimate tissue cystine content in nephropathic cystinosis.
Dohil R; Carrigg A; Newbury R
J Pediatr; 2012 Sep; 161(3):531-535.e1. PubMed ID: 22513268
[TBL] [Abstract][Full Text] [Related]
35. [Intra-leukocyte cystine in cystinosis treated with cysteamine].
Ged C; Jean G; Tete MJ; Broyer M; Kamoun P
Ann Biol Clin (Paris); 1991; 49(9):482-6. PubMed ID: 1789502
[TBL] [Abstract][Full Text] [Related]
36. The Pitfall of White Blood Cell Cystine Measurement to Diagnose Juvenile Cystinosis.
Bondue T; Kouraich A; Berlingerio SP; Veys K; Marie S; Alsaad KO; Al-Sabban E; Levtchenko E; van den Heuvel L
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674769
[TBL] [Abstract][Full Text] [Related]
37. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.
Brodin-Sartorius A; Tête MJ; Niaudet P; Antignac C; Guest G; Ottolenghi C; Charbit M; Moyse D; Legendre C; Lesavre P; Cochat P; Servais A
Kidney Int; 2012 Jan; 81(2):179-89. PubMed ID: 21900880
[TBL] [Abstract][Full Text] [Related]
38. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].
Kaufeld J; Weber LT; Kurschat C; Canaan-Kuehl S; Brand E; Oh J; Pape L
Internist (Berl); 2018 Aug; 59(8):861-867. PubMed ID: 29671012
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological treatment of nephropathic cystinosis with cysteamine.
Kleta R; Gahl WA
Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
[TBL] [Abstract][Full Text] [Related]
40. A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study.
Liang H; Labbé A; Le Mouhaër J; Plisson C; Baudouin C
Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2275-2283. PubMed ID: 28426870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
